Grant: Doctoral Award - Doctoral Foreign Study Award (DFSA)
Direct Payment
$105,000.00
Defining Synthetic Lethal Genes in YAP/TAZ-Dependent Breast Cancers
FY 2016-17
Summary
Breast cancer, the most common cancer in women worldwide, is the second leading cause of female cancer death in North America. Despite advances in therapy, breast cancer remains a significant cause of mortality, and improved treatments utilizing novel approaches are needed.
One characteristic of breast cancer cells that distinguishes them from normal cells is that they are often tetraploid, a condition where cells harbor twice the normal number of chromosomes. Normally, tetraploid cells fail to proliferate. However, our lab recently demonstrated that inactivation of a cellular pathway termed the Hippo pathway restores proliferative ability to tetraploid cells.
The Hippo pathway controls cell proliferation by regulating two proteins, YAP and TAZ, which can enter the nucleus of a cell and activate growth-promoting genes. When the Hippo pathway is active, it prevents these proteins from entering the nucleus and thus restrains cell division. Conversely, when the Hippo pathway is inactivated, YAP/TAZ accumulate in the nucleus to turn on pro-growth genes. Breast cancer cells frequently show abnormally high levels of YAP/TAZ in their nucleus. This suggests that a common, and perhaps requisite, feature of breast cancers is that they inactivate the Hippo pathway to drive growth. However, whether these cells are dependent on YAP/TAZ for their survival is unknown. In addition, the genes turned on by YAP/TAZ that are critical for tumour growth are poorly resolved.
Our proposal aims to find new drug targets in YAP/TAZ-driven breast cancers. To this end, we will characterize YAP/TAZ dependency across a cohort of breast cancer cell lines and identify key genes that differentially drive the growth and survival of YAP/TAZ-dependent cell lines. These genes represent novel drug targets whose identification holds the potential to enable the selective killing of tetraploid breast cancer cells dependent on YAP/TAZ, while sparing the non-cancerous diploid cells around them.
Department
Program
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Recipient
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
365409
Name
Quinton Ryan
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Defining Synthetic Lethal Genes in YAP/TAZ-Dependent Breast Cancers
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Keyworddelim
Aneuploidy; Hippo Pathway; Oncogene Addiction; Synthetic Lethality; Taz; Tetraploidy; Yap
Abstract
Breast cancer, the most common cancer in women worldwide, is the second leading cause of female cancer death in North America. Despite advances in therapy, breast cancer remains a significant cause of mortality, and improved treatments utilizing novel approaches are needed.
One characteristic of breast cancer cells that distinguishes them from normal cells is that they are often tetraploid, a condition where cells harbor twice the normal number of chromosomes. Normally, tetraploid cells fail to proliferate. However, our lab recently demonstrated that inactivation of a cellular pathway termed the Hippo pathway restores proliferative ability to tetraploid cells.
The Hippo pathway controls cell proliferation by regulating two proteins, YAP and TAZ, which can enter the nucleus of a cell and activate growth-promoting genes. When the Hippo pathway is active, it prevents these proteins from entering the nucleus and thus restrains cell division. Conversely, when the Hippo pathway is inactivated, YAP/TAZ accumulate in the nucleus to turn on pro-growth genes. Breast cancer cells frequently show abnormally high levels of YAP/TAZ in their nucleus. This suggests that a common, and perhaps requisite, feature of breast cancers is that they inactivate the Hippo pathway to drive growth. However, whether these cells are dependent on YAP/TAZ for their survival is unknown. In addition, the genes turned on by YAP/TAZ that are critical for tumour growth are poorly resolved.
Our proposal aims to find new drug targets in YAP/TAZ-driven breast cancers. To this end, we will characterize YAP/TAZ dependency across a cohort of breast cancer cell lines and identify key genes that differentially drive the growth and survival of YAP/TAZ-dependent cell lines. These genes represent novel drug targets whose identification holds the potential to enable the selective killing of tetraploid breast cancer cells dependent on YAP/TAZ, while sparing the non-cancerous diploid cells around them.
Competitiondate
201610
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Quinton, Ryan
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~